Dosimetric evidences of 131I-MIBG treatment in High Risk Neuroblastoma in VERITAS protocol

被引：0
|
作者：
Saletti, P. [1 ]
Olianti, C. [1 ]
Tondo, A. [2 ]
Simontacchi, G. [1 ]
Belli, G. [1 ]
机构：
[1] AOU Careggi, Florence, Italy
[2] AOU Meyer, Florence, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-702
引用
收藏
页码：S225 / S225
页数：1
相关论文
共 50 条
  • [1] The Role of 131I-MIBG in High-Risk Neuroblastoma Treatment
    Lessig, Megan Kinnear
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2009, 26 (04) : 208 - 216
  • [2] Dosimetric evaluation of Neuroblastoma patients submitted to 131I-MIBG
    Rezio, M. T.
    Ferreira, T. C.
    Salgado, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S429 - S429
  • [3] Upfront Treatment of High-Risk Neuroblastoma With a Combination of 131I-MIBG and Topotecan
    Kraal, Kathelijne C. J. M.
    Tytgat, Godelieve A. M.
    van Eck-Smit, Berthe L. F.
    Kam, Boen
    Caron, Huib N.
    van Noesel, Max
    PEDIATRIC BLOOD & CANCER, 2015, 62 (11) : 1886 - 1891
  • [4] Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG
    Sudbrock, F.
    Eschner, W.
    Schmidt, M.
    Simon, T.
    Hero, B.
    Schicha, H.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2006, 45 (06): : 254 - 261
  • [5] Dosimetric analysis and clinical outcome for patient with High-Risk Neuroblastoma administered with high-activity therapy of 131I-mIBG
    Cassano, B.
    Polito, C.
    Genovese, E.
    Longo, M.
    Donatiello, S.
    Napolitano, A.
    Insero, T.
    Valeri, S.
    Villani, M. F.
    Castellano, A.
    Garganese, M. C.
    Cannata, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S195 - S196
  • [6] Biomarker Modulations in Children With Neuroblastoma Following Treatment With 131I-mIBG
    Imber, B. S.
    Olow, A.
    Karski, E. E.
    Allen, I. E.
    DuBois, S. G.
    Haas-Kogan, D. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S729 - S730
  • [7] Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma
    Anongpornjossakul, Yoch
    Sriwatcharin, Wattanun
    Thamnirat, Kanungnij
    Chamroonrat, Wichana
    Kositwattanarerk, Arpakorn
    Utamakul, Chirawat
    Sritara, Chanika
    Chokesuwattanasakul, Payap
    Thokanit, Nintita Sripaiboonkij
    Pakakasama, Samart
    Anurathapan, Usanarat
    Pongphitcha, Pongpak
    Chotipanich, Chanisa
    Hongeng, Suradej
    NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (04) : 336 - 343
  • [8] TREATMENT OUTCOME OF HIGH DOSE 131I-MIBG TREATMENT IN STAGE 4 NEUROBLASTOMA IN HONG KONG
    Leung, Wine Kwan
    Lee, Vincent
    Kam, Michael
    Cheng, Frankie Wai Tsoi
    Shing, Ming Kong
    Li, Chi Kong
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 784 - 785
  • [9] Is there a benefit of 131I-MIBG therapy FOR in the treatment of children with stage 4 neuroblastoma?
    Schmidt, M.
    Simon, T.
    Hero, B.
    Eschner, W.
    Dietlein, M.
    Sudbrock, F.
    Bongartz, R.
    Berthold, F.
    Schicha, H.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2006, 45 (04): : 145 - 151
  • [10] NURSING CARE ISSUES DURING 131I-MIBG TREATMENT FOR ADVANCE NEUROBLASTOMA
    Lam, C.
    Cheng, K.
    Cheung, J.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 186 - 186
12345